Email: support@essaywriterpros.com
Call Us: US - +1 845 478 5244 | UK - +44 20 7193 7850 | AUS - +61 2 8005 4826

The life expectancy

Trisomy 13, also called Patau syndrome, is a chromosomal condition associated with severe intellectual disability and physical abnormalities in many parts of the body. Individuals with trisomy 13 often have heart defects, brain or spinal cord abnormalities, very small or poorly developed eyes (microphthalmia), extra fingers and/or toes, an opening in the lip (a cleft lip) with or without an opening in the roof of the mouth (a cleft palate) and weak muscle tone (hypotonia). The risk of having a child with trisomy 13 increases with a mother’s age. (Genetics Home Reference, November 2013) Patau syndrome can also be caused by translocation. Routine screening tests for trisomies 21, 18 and 13 include first-trimester screening (which involves an ultrasound and a blood test), maternal serum screening (a blood test) and a high-resolution ultrasound evaluation in the second trimester. These tests may identify women with an increased risk of having a child with trisomy 21, 18 or 13, but they cannot diagnose, confirm or exclude the possibility of a chromosomal disorder. Conventional prenatal diagnosis (i.e., chorionic villus sampling (CVS) or amniocentesis) can definitively diagnose fetal trisomies, although these invasive procedures are associated with a risk of miscarriage. (Hayes, 2015) Tests that detect fetal trisomies, without the need for CVS or amniocentesis, analyze cell-free DNA (cfDNA) fragments in maternal blood. During pregnancy, there are cfDNA fragments from both the mother and fetus in maternal circulation. The tests detect an increased amount of chromosomal material in maternal blood and can be offered as early as 10 weeks of pregnancy. Available tests use different methodologies and algorithms for data analysis. Depending on the test, the methodology may involve massively parallel sequencing (MPS), targeted sequencing of specific chromosomal segments or directed sequence analysis of single nucleotide polymorphisms (SNPs). (Hayes, 2015) All tests were validated in high-risk couples. It is unknown whether they are as accurate for low- to averagerisk couples.